Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28984052 | 0.78 | LPL (0.37) | LPLLIPGCXCR2JAK2BTK | |
| SCHEMBL30615277 | 0.78 | JAK2 (0.37) | LPLLIPGCXCR2JAK2BTK | |
| SCHEMBL17951295 | 0.78 | JAK2 (0.37) | LPLLIPGCXCR2JAK2BTK | |
| SCHEMBL20237032 | 0.78 | JAK2 (0.37) | LPLLIPGCXCR2JAK2BTK | |
| SCHEMBL29414892 | 0.77 | BACE1 (0.34) | LPLLIPGCXCR2JAK2BTK | |
| SCHEMBL29095166 | 0.77 | CXCR2 (0.36) | LIPGCXCR2JAK2BTK | |
| SCHEMBL18483425 | 0.77 | BACE1 (0.34) | LPLLIPGCXCR2JAK2BTK | |
| SCHEMBL24630498 | 0.77 | LPL (0.46) | LPLLIPGJAK2BTK | |
| SCHEMBL29083945 | 0.76 | — | — | |
| SCHEMBL28530415 | 0.75 | LPL (0.38) | LPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20190337962-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | UBE INDUSTRIES, LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-3333163-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | LPL 3017/4885LIPG 2496/4885CXCR2 450/4885 |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | GMPS, GUCY1A1, GUCY1A2 | LPL 3017/4885LIPG 2496/4885CXCR2 450/4885 |
| US-20190337962-A1 | SUBSTITUTED GUANIDINE COMPOUNDS | GMPS, PDE3B, GUCY1A2 | LPL 2581/4885LIPG 2007/4885CXCR2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.